SOD1 and amyotrophic lateral sclerosis: Related to these topics, ATLAS, an ongoing randomized, placebo-controlled, phase 3 trial, aims to study if Tofersen can delay the manifestation of ALS symptoms in presymptomatic SOD1 variant carriers [57].